15 AmBisome® (LAmB), a liposomal formulation of amphotericin B (AmB), is a second-line 16 treatment for the parasitic skin disease cutaneous leishmaniasis (CL). Little is known about 17 its tissue distribution and pharmacodynamics to inform clinical use in CL. Here, we 18 compared the skin pharmacokinetics of LAmB with Fungizone® (DAmB), the deoxycholate 19 form of AmB, in murine models of Leishmania major CL. Drug levels at the target site (the 20 localized lesion) 48 hours after single intravenous (IV) dosing of the individual AmB 21
INTRODUCTION
Version 5 (November 2017) -corrected after review to extract parasite DNA from lesions and quantify parasite load by qPCR has already been 130 described in full detail earlier (13).
131
Skin sample collection and preparation. After sacrificing mice (CO 2 ), skin was harvested 132 by surgical removal from the areas containing the localized CL lesion (at the parasite 133 inoculation site on the rump above the tail, 'lesion-site') and CL-uninfected skin on the back 134 ('control site'). The skin tissue was cut into fine, long pieces and placed into SureLock (2 µl of a 1000 units/ml stock (aq)). After centrifugation at 6500 rpm at 4 °C for 10 minutes, (542 ± 46 ng/g) were 3-fold higher than for DAmB (170 ± 18 ng/g, p<0.0001). Comparing 214 these concentrations 48 hours after the last dosing to those found during earlier single dose 215 PK studies at the same time point (see figure 1c and 1d -LamB: 110 ± 17 ng/g; DAmB: 92 ± 216 4 ng/g), a gradual and linear drug accumulation in the target tissue during treatment can be 217 assumed for LAmB but not for DAmB. Again, AmB levels in the lesion were significantly 218 higher compared to those in the healthy back skin for LAmB (x 20, p<0.0001) and DAmB (x 219 12, p<0.0001).
We then compared the resulting efficacy outcomes for LAmB and DAmB after complete 5 x 221 1 mg/kg treatment. A small reduction in day 10 lesion size compared to the untreated (5% 222 dextrose) group (9.9 ± 0.8 mm) was found for LAmB (9.4 ± 0.2 mm) and DAmB (8.7 ± 0.6), 223 but in both cases the difference was not significant (p=0.83 and 0.34, respectively). A lower 224 relative parasite load was also found for LAmB (2.0 ± 0.6 x 10 7 parasites/g) and DAmB (6.1 225 ± 3.4 x 10 7 parasites/g), but again without a statistically significant difference compared to 226 the control (1.6 ± 0.5 x 10 8 parasites/g, p=0.12 and 0.23 respectively). As expected, both 227 formulations show some antileishmanial efficacy at 5 x 1 mg/kg, but the toxicity limit of Little is known about the elimination of AmB from the target site by local metabolism or lymphatic drainage. However, the latter has been hypothesized as a reason behind the much 283 lower activity of liposomal formulations of AmB (12) and sodium stibogluconate (22) when 284 injected intralesionally compared to intravenously. The impact of these individual 285 physiological processes on local drug distribution in skin is difficult to estimate using the 286 current methodology, which is based on total drug levels and unable to distinguish between 287 intra-or extracellular, as well as free, protein-bound or liposome-encapsulated AmB. 
